US Court Orders Actavis (ACT) To Resume Sales Of Alzheimer’s Drug

December 12, 2014 2:44 PM

11 0

Actavis has been told to resume sales of its Alzheimer’s drug, Namenda. This is intended to prevent the company from its planned “forced switch”

On Thursday, Actavis plc (NYSE:ACT) was handed an unfavorable ruling by a US federal court judge, who mandated the company continue to sell the older version of Alzheimer’s drug, Namneda IR (immediate-release), which was taken off the market a few months ago. The lawsuit accused the company of dupli...

Read more

To category page